Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03211234 · ClinicalTrials.gov registry record · Phase 2
Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects
A Phase 2 study, sponsored by Santen.
- Completed
- Registry status
- Phase 2
- Development phase
- 76
- Enrollment target
NCT03211234 is a Phase 2 study that has completed, run by Santen. The registered enrollment target is 76 participants.
The verdict
NCT03211234, a Phase 2 study, has completed, sponsored by Santen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 76 participants
- Enrollment target
Study Summary
To assess the safety and efficacy of repeated intravitreal injections of DE-122 (low dose and high dose) given in combination with Lucentis® in subjects with wet age-related macular degeneration (AMD) compared with Lucentis® alone.
Interventions
- DRUG Lucentis
- DRUG 2.0 mg DE-122 Injectable Solution + Lucentis
- DRUG 4.0 mg DE-122 Injectable Solution + Lucentis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2017-07-05 |
| Est. Completion | 2020-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03211234
The ClinicalTrials.gov registry entry for NCT03211234 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Santen, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Lucentis is the first listed.
NCT03211234 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03211234 about?
NCT03211234 is a clinical study titled "Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects". To assess the safety and efficacy of repeated intravitreal injections of DE-122 (low dose and high dose) given in combination with Lucentis® in subjects with wet age-related macular degeneration (AMD) compared with Lucentis® alone.
What is the current status of trial NCT03211234?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2017-07-05. Estimated completion is 2020-01-31.
What interventions are being tested in trial NCT03211234?
The interventions under investigation include: Lucentis (DRUG), 2.0 mg DE-122 Injectable Solution + Lucentis (DRUG), 4.0 mg DE-122 Injectable Solution + Lucentis (DRUG).
Who is sponsoring clinical trial NCT03211234?
This trial is sponsored by Santen, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.